Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. PFE
PFE logo

PFE

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

PFE News

Pfizer's Dividend Safety Faces Challenges Amid High Payout Ratio

2h agoFool

Olema Pharmaceuticals Stock Declines Following Clinical Trial Setback

4h agoBenzinga

Pfizer and Eli Lilly's Strategic Moves in AI Healthcare

5h agoFool

Pfizer's Tilrekimig Phase 2 Study Shows Positive Results

6h agoseekingalpha

Surge in Oil Prices Triggers Market Turmoil

8h agoCNBC

Bristol Myers Squibb Highlights from 2025 Earnings Report

20h agoNASDAQ.COM

Bristol Myers Squibb Maintains Positive Outlook for 2026

21h agoFool

FDA Vaccines Head Vinay Prasad to Depart Again

2d agoseekingalpha

Amarin Faces Challenges, Restructures for Survival

2d agoFool

Amarin Faces Patent Loss and Competitive Pressures

2d agoNASDAQ.COM

Regencell Bioscience Market Risk Analysis

2d agoFool

Regencell Bioscience Faces High-Risk Investment Landscape

2d agoNASDAQ.COM

FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism

2d agoCNBC

Capricor Therapeutics Options Show Significant Volume Activity

3d agoNASDAQ.COM

Supreme Court Overturns Trump's Tariffs, Economic Implications Ahead

3d agoFool

Democratic Senators Question Pharma Price Deals with Trump Administration

3d agoseekingalpha